EGFR Exon 19 Deletion Mutation (DBCOND0090107)

Identifiers

Synonyms

EGFR (Epidermal Growth Factor Receptor) Exon 19 Deletion Mutation / EGFR exon 19 deletion / EGFR gene mutation / Epidermal growth factor receptor gene mutation

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Afatinib	An antineoplastic agent used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations or resistance to platinum-based chemotherapy.	Epidermal growth factor receptortarget Receptor tyrosine-protein kinase erbB-2target Receptor tyrosine-protein kinase erbB-4target ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter
Dacomitinib	A medication used to treat non small cell lung cancer with EGFR exon 19 deletion of exon 21 L858R substitution.	Cytochrome P450 2D6enzyme Albumincarrier Cytochrome P450 3A4enzyme Cytochrome P450 2C9enzyme UDP-glucuronosyltransferase 1A1enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier family 22 member 1transporter Epidermal growth factor receptortarget Receptor tyrosine-protein kinase erbB-4target Receptor tyrosine-protein kinase erbB-2target
Ramucirumab	An antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.	Vascular endothelial growth factor receptor 2target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT01532089	Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations	Bevacizumab Erlotinib	treatment	2	completed
NCT05998993	Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)	No drug interventions	treatment	Not Available	not_yet_recruiting
NCT04862780	(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	Osimertinib Tigozertinib	treatment	1 / 2	active_not_recruiting
NCT05338970	HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy	Platinum	treatment	3	active_not_recruiting
NCT05153408	(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC	Carboplatin Osimertinib Pemetrexed	treatment	1	terminated